A panel of 48 CSF proteins—Aβ or tau not among them—distinguished people with Alzheimer’s from controls with 94 percent accuracy, according to a study published September 6 in Science Translational Medicine. Adding classic AD biomarkers to this curated panel bumped up accuracy even more. The work was led by Thomas Wingo, Nicholas Seyfried, and Allan Levey at Emory University in Atlanta. Read more at https://news.emory.edu/stories/2023/09/hs_alzheimers_biomarkers_14_09_23/story.html
CSF Proteomic Panel Better Predicts Decline Than Do Classic AD Biomarkers
